Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients
Christopher M Rubino1, Anthony P Cammarata1, Anne Smits2,3
1Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Antimicrobial Agents and Chemotherapy
|August 16, 2021
Summary
This study developed a pharmacokinetic model for ceftobiprole in pediatric patients to optimize dosing for pneumonia treatment. Recommended doses ensure adult-like exposure and effective treatment across different pediatric age groups.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Pharmacokinetics
Background:
- Ceftobiprole is an advanced-generation cephalosporin antibiotic.
- Effective dosing in pediatric populations requires careful consideration of pharmacokinetic variability.
Purpose of the Study:
- To develop a population pharmacokinetic (PK) model for ceftobiprole in pediatric patients.
- To use model-based simulations to optimize ceftobiprole dosage for treating pediatric pneumonia.
Main Methods:
- A population PK model was developed using data from 107 pediatric patients (0-17 years).
- The model described ceftobiprole disposition using a three-compartment model with linear elimination.
- Clearance was modeled as a function of glomerular filtration rate; other parameters were weight-scaled.
Main Results:
- The population PK model robustly described ceftobiprole disposition in pediatric patients.
- Simulations suggested a 15 mg/kg dose every 12 or 8 hours for most pediatric patients to achieve adult-like exposure.
- Lower doses (10 mg/kg every 12 hours) are recommended for neonates/infants <3 months and <4 kg.
Conclusions:
- The developed population PK model provides a reliable basis for ceftobiprole dosing in pediatric patients.
- Optimized dosing regimens are proposed to ensure pharmacokinetic-pharmacodynamic target attainment for pediatric pneumonia treatment.
- Adjusted dosing is necessary for younger infants, low-weight neonates, and pediatric patients with renal impairment.
More Related Videos
Related Concept Videos
01:29Drug Dosing: Infants and Children
55
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
55
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
44
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
44
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
46
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
46
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
39
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
39
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
56
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
56
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
42
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
42